- Home
- ANTX vs ALGS Comparison
ANTX vs ALGS Comparison
Compare ANTX & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- ALGS
- Stock Information
- Founded
- ANTX 2017
- ALGS 2018
- Country
- ANTX United States
- ALGS United States
- Employees
- ANTX N/A
- ALGS N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- ALGS Health Care
- Exchange
- ANTX Nasdaq
- ALGS Nasdaq
- Market Cap
- ANTX 37.6M
- ALGS 38.8M
- IPO Year
- ANTX 2022
- ALGS 2020
- Fundamental
- Price
- ANTX $1.41
- ALGS $10.28
- Analyst Decision
- ANTX Hold
- ALGS Strong Buy
- Analyst Count
- ANTX 5
- ALGS 1
- Target Price
- ANTX $3.50
- ALGS $70.00
- AVG Volume (30 Days)
- ANTX 168.1K
- ALGS 208.8K
- Earning Date
- ANTX 03-27-2025
- ALGS 03-10-2025
- Dividend Yield
- ANTX N/A
- ALGS N/A
- EPS Growth
- ANTX N/A
- ALGS N/A
- EPS
- ANTX N/A
- ALGS N/A
- Revenue
- ANTX N/A
- ALGS $3,945,000.00
- Revenue This Year
- ANTX N/A
- ALGS N/A
- Revenue Next Year
- ANTX N/A
- ALGS N/A
- P/E Ratio
- ANTX N/A
- ALGS N/A
- Revenue Growth
- ANTX N/A
- ALGS N/A
- 52 Week Low
- ANTX $0.87
- ALGS $6.76
- 52 Week High
- ANTX $3.88
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- ANTX 72.16
- ALGS 22.89
- Support Level
- ANTX $1.09
- ALGS $9.51
- Resistance Level
- ANTX $1.39
- ALGS $11.17
- Average True Range (ATR)
- ANTX 0.06
- ALGS 1.65
- MACD
- ANTX 0.03
- ALGS -0.27
- Stochastic Oscillator
- ANTX 94.20
- ALGS 8.12
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.